Chemed (CHE) Looks Repriced As Raised Guidance And Margin Gains Lift The Narrative

Chemed (CHE) is back in focus after a strong third quarter, with higher profit, rising earnings per share and a guidance raise that, together with an analyst upgrade, has stirred fresh interest in the stock.

Chemed's recent earnings beat and guidance raise have come alongside firm price momentum, with a 1-month share price return of 5.83% and a year-to-date share price gain of 27.87%. This contrasts with a softer 3-year total shareholder return, which declined 5.27%.

Compare Chemed's momentum and guidance story with a hand-picked 18 high quality undiscovered gems that are also drawing attention after fresh earnings shifts and analyst upgrades.

Bulls see Chemed's guidance raise and analyst upgrade as a sign the rerating has further to run. Bears point to the weaker 3-year return. Which side does today's valuation actually support?

Most Popular Narrative: 9% Undervalued

Chemed closed at $541.92, while the most followed narrative pegs fair value closer to $592.60. The market is pricing in a discount that hinges on how the hospice and Roto-Rooter stories play out from here.

Chemed is still aggressively adjusting its patient mix and operational processes at VITAS to mitigate Medicare Cap billing limitations, and the reported Cap cushion in Florida alongside reduced expected Cap charges indicates progress that can support higher net margins and earnings.

Ongoing investment in technology, cost management, and process optimization at both VITAS and Roto Rooter, including centralized billing and tighter KPIs, is now feeding through to lower write offs and leaner headcount, which can support EBITDA margin resilience and earnings.

See why 1 investors see Chemed as 9% undervalued .

Result: Fair Value of $592.60 (UNDERVALUED)

Still, the Chemed narrative can shift quickly if Medicare reimbursement rules tighten again or if Roto Rooter's higher lead costs continue to pressure profitability.

Find out about the key risks to this Chemed narrative .

Next Steps

Mixed signals on Chemed leave room for debate, so move quickly, review the underlying metrics and sentiment yourself, then weigh up the 3 key rewards and 1 important warning sign .

Looking for more ideas beyond Chemed?

If you only focus on Chemed, you risk missing other compelling setups that line up with your goals and preferred balance of quality, income and risk.

• Target resilient compounding by scanning a 30 high quality undervalued stocks that blends quality fundamentals with prices that sit below intrinsic worth estimates.

• Lock in potential income streams by reviewing a 7 dividend fortresses that screens for stronger yield combined with balance sheet support.

• Dial down portfolio stress by filtering for a 30 resilient stocks with low risk scores that emphasizes sturdier financial profiles and steadier trading behavior.